A phase 1 study of HT-KIT in adult patients with advanced systemic mastocytosis (AdvSM)
Latest Information Update: 04 Oct 2023
At a glance
- Drugs HT-KIT (Primary)
- Indications Systemic mastocytosis
- Focus Adverse reactions; First in man
- 02 Oct 2023 According to a Hoth Therapeutics media release, the Pre-IND meeting requested on September 8th for HT-KIT with the U.S. Food and Drug Administration (FDA) has been granted to receive written responses only from the FDA that are targeted for delivery on November 7, 2023.
- 14 Sep 2023 New trial record
- 11 Sep 2023 According to a Hoth Therapeutics media release, the plans to present clinical trial designs for the IND-opening and phase 1 studies